Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 16/20 | 0.55 |
| ▸ | KCNJ5 | P48544 | 16/20 | 0.55 |
| ▸ | KCNJ3 | P48549 | 16/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239340 | 0.90 | KCNA5 (0.52) | KCNA5KCNJ5KCNJ3MAPTL3MBTL1 | |
| SCHEMBL3516632 | 0.84 | KCNA5 (0.58) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL3515653 | 0.83 | KCNA5 (0.54) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL3517246 | 0.83 | KCNA5 (0.54) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL1239786 | 0.83 | KCNA5 (0.51) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL12080254 | 0.83 | KCNA5 (0.44) | KCNA5KCNJ5KCNJ3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3519870 | 0.82 | KCNA5 (0.54) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL3519033 | 0.82 | KCNA5 (0.54) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL12080653 | 0.82 | KCNA5 (0.55) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL3519222 | 0.82 | KCNA5 (0.53) | KCNA5KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254873-B1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8664217-B2 | Benzodiazepine compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20130040941-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. | 2013-02-14 | — | — | US | disclosed |
| US-8338406-B2 | Benzodiazepine compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | KCNA5, KCNA1, KCNAB1 | KCNA5 1/4885KCNJ5 12/4885KCNJ3 35/4885 |
| US-20130040941-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | KCNA5, KCNA1, KCNAB1 | KCNA5 1/4885KCNJ5 12/4885KCNJ3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.